午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >LB100
LB100
  • LB100

LB100 NEW

Price $51 $108 $198
Package 1mg 5mg 10mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: LB100 CAS No.: 1632032-53-1
Purity: 98.63% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameLB100
DescriptionLB100 (LB-100) is a water soluble protein phosphatase 2A (PP2A) inhibitor.
Cell ResearchCytotoxicity is conducted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of 3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity is expressed as a percentage of speci?c controls. (Only for Reference)
Kinase AssayPP2A activity assays: Cultured pancreatic cancer cells are treated with IC50 of LB-100 for each cell line or equal volume of vehicle for 2 hours, and PP2A activity assays are then performed using Ser/Thr phosphatase assay kit. Cells are lysed with an ultrasonic cell disruptor, and the PP2A concentration is measured using a Ser/Thr phosphatase assay kit according to the instructions. Assays for each cell line are performed in triplicate.
In vitroIn xenograft mouse models of pancreatic cancer, LB-100 (2 mg/kg, i.p.) enhances the therapeutic efficacy of the chemotherapy agent doxorubicin. LB-100 increases both the blood flow velocity on the tumor surface and the microvascular density of the tumor.
In vivoCompared to the control group, LB-100 significantly increased the intracellular concentration of doxorubicin by approximately 2.5 times, enhancing the tumor cells' sensitivity to doxorubicin. Additionally, LB-100 amplified the secretion of vascular endothelial growth factor, thereby promoting angiogenesis mediated by HIF-1α-VEGF. LB-100 also demonstrated a notable inhibitory effect on the growth of BxPc-3 (IC50: 2.3 μM) and Panc-1 (IC50: 1.7 μM) cells. Following treatment with LB-100, a reduction of 30-50% in PP2A activity was observed in BxPc-3, SW1990, and Panc-1 tumor cells.
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationH2O : 49 mg/mL (182.6 mM)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
KeywordsLB100
Inhibitors RelatedPTP1B-IN-22 | Disodium monofluorophosphate | β-Glycerophosphate disodium salt pentahydrate | MLS000544460 | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | Trimyristin | β-Glycerophosphate disodium salt hydrate
Related Compound LibrariesGlycometabolism Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$/
Anhui Ruihan Technology Co., Ltd
2023-08-21
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY